Cassava Sciences | PTIE - Ebitda

Aktienkurs
1.79
Täglich Wechseln
-0.04 -2.19%
Monatlich
-17.13%
Jährlich
-36.97%
Q1 Prognose
1.74




Ebitda Veränderung Datum
Abbott USD 3.09B 44M 2025-09
Amgen USD 5.14B 775M 2025-12
Biogen USD 573.2M 253.7M 2025-12
Cara Therapeutics USD -2.39M 3.16M 2025-03
Cassava Sciences USD -11.73M 33.44M 2025-09
Eisai JPY 30.1B 6.62B 2025-12
Eli Lilly USD 7.88B 378.1M 2025-09
Geron USD -9.47M 1.92M 2025-09
J&J USD 9.52B 389M 2025-09
Merck USD 8.39B 1.97B 2025-09
Novartis USD 4.77B 1.11B 2025-12
Novavax USD 19.36M 190.79M 2025-12
Pfizer USD 6.08B 351M 2025-09
Roche Holding CHF 12.68B 2.36B 2024-06